Core Viewpoint - The Chinese pharmaceutical industry is transitioning from "generic following" to "innovative leading," with a significant increase in original innovative drugs expected in 2024, reaching 704, ranking first globally [2]. Industry Overview - The Chinese pharmaceutical sector is entering a "golden decade" following the new clinical data verification policy implemented on July 22, with continuous policy support fostering a comprehensive support system for the industry [2]. - The industry is witnessing a strategic opportunity driven by "innovation" and "internationalization" as core forces [2]. Company Strategy - The company, Dongyang Sunshine Pharmaceutical, is focusing on source innovation, with a research pipeline that includes small molecules, antibodies, small nucleic acids, ADCs, and cell therapies [2]. - The research strategy has shifted from "Me-too" and "Fast-follow" to pursuing "BIC" (Best-in-Class) and "FIC" (First-in-Class) [2]. - Dongyang Sunshine has nearly 50 research pipelines, with over 10 in registration or critical clinical stages, showcasing potential products with differentiated advantages and international competitiveness [2]. Technological Innovation - The company is leveraging the AI wave by developing six AI models, enabling a full-chain drug discovery capability from molecular design to formulation design [3]. - The first AI-driven small molecule innovative drug, HEC169584, has entered clinical trials, showing potential superiority over comparator drugs [3]. Core Technology Platforms - Dongyang Sunshine has established multiple core technology platforms, including TCE bispecific antibodies, dual payload ADCs, and small nucleic acids, aimed at addressing significant unmet clinical needs such as solid tumor treatment and hepatitis B cure [4]. Internationalization Strategy - The company views internationalization as essential for the development of Chinese innovative pharmaceutical companies, employing a diversified strategy for overseas expansion [5]. - This includes "License-out" agreements for some new drugs and promoting self-developed products in Europe and the U.S., with the expectation that insulin glargine will be approved in the U.S. by Q1 2026 [5]. Future Outlook - Dongyang Sunshine has established a global sales network, with over 60 overseas formulations approved, and a leading market share for azithromycin tablets in Germany [6]. - The company aims to achieve over 20 billion yuan in revenue and 5 billion yuan in profit within five years, launching more than 10 new products and securing over five global collaborations [6]. - The essence of the advancement of Chinese pharmaceutical companies lies in the global recognition and validation of innovative value [6].
东阳光药张英俊：以“创新+国际化”双引擎开启中国药企进阶新篇章